Catalent (NYSE:CTLT) Lowered to Sell Rating by StockNews.com

StockNews.com cut shares of Catalent (NYSE:CTLT) from a hold rating to a sell rating in a research report sent to investors on Friday.

CTLT has been the topic of several other research reports. William Blair restated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Robert W. Baird reissued a “neutral” rating and set a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. Finally, Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating and seven have given a hold rating to the company. According to MarketBeat.com, Catalent has an average rating of “Hold” and an average price target of $63.40.

Catalent Trading Up 2.2 %

Shares of CTLT stock opened at $60.98 on Friday. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The company has a market capitalization of $11.07 billion, a P/E ratio of -26.98, a P/E/G ratio of 2.34 and a beta of 1.16. Catalent has a 12-month low of $36.74 and a 12-month high of $61.50. The firm has a 50-day moving average price of $59.79 and a 200 day moving average price of $58.26.

Catalent (NYSE:CTLT) last posted its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business’s revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.10) EPS. Research analysts forecast that Catalent will post 0.84 earnings per share for the current fiscal year.

Insider Activity at Catalent

In other Catalent news, insider David Mcerlane sold 1,994 shares of the stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now owns 36,304 shares in the company, valued at approximately $2,177,150.88. This represents a 5.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the sale, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 5,114 shares of company stock worth $305,931. 0.31% of the stock is owned by company insiders.

Institutional Investors Weigh In On Catalent

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Neo Ivy Capital Management acquired a new position in Catalent during the 3rd quarter worth approximately $1,078,000. Nomura Asset Management Co. Ltd. lifted its position in shares of Catalent by 1.4% in the third quarter. Nomura Asset Management Co. Ltd. now owns 53,011 shares of the company’s stock worth $3,211,000 after purchasing an additional 750 shares in the last quarter. National Bank of Canada FI boosted its holdings in Catalent by 300.0% during the third quarter. National Bank of Canada FI now owns 1,460,813 shares of the company’s stock worth $88,481,000 after purchasing an additional 1,095,578 shares during the last quarter. State Street Corp grew its position in Catalent by 1.5% in the third quarter. State Street Corp now owns 7,451,135 shares of the company’s stock valued at $451,315,000 after purchasing an additional 113,095 shares in the last quarter. Finally, Quantinno Capital Management LP increased its stake in Catalent by 30.6% in the 3rd quarter. Quantinno Capital Management LP now owns 16,290 shares of the company’s stock valued at $987,000 after buying an additional 3,817 shares during the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.